[go: up one dir, main page]

IN2012DN03391A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03391A
IN2012DN03391A IN3391DEN2012A IN2012DN03391A IN 2012DN03391 A IN2012DN03391 A IN 2012DN03391A IN 3391DEN2012 A IN3391DEN2012 A IN 3391DEN2012A IN 2012DN03391 A IN2012DN03391 A IN 2012DN03391A
Authority
IN
India
Prior art keywords
compound
methyl
processes
relates
luoro
Prior art date
Application number
Inventor
David Cantin Louis
Luo Xuehong
Jerzy Tomaszewski Miroslaw
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IN2012DN03391A publication Critical patent/IN2012DN03391A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This invention generally relates to substituted benzoimidazole compounds, particularly methyl 2-((2-(2,6-di£luoro-4-(methylcarbamoyl)phenyl)-5-methyl-lH-benzo[d]imidazol-l-yl)methyl)morpholine-4-carboxylate and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processes for making such a compound, and intermediates used in such processes.
IN3391DEN2012 2009-11-18 2010-11-17 IN2012DN03391A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26226309P 2009-11-18 2009-11-18
PCT/SE2010/051269 WO2011062550A1 (en) 2009-11-18 2010-11-17 Benzoimidazole compounds and uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN03391A true IN2012DN03391A (en) 2015-10-23

Family

ID=44059844

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3391DEN2012 IN2012DN03391A (en) 2009-11-18 2010-11-17

Country Status (16)

Country Link
US (1) US8530467B2 (en)
EP (1) EP2501697B1 (en)
JP (1) JP5657018B2 (en)
KR (1) KR20120113709A (en)
CN (1) CN102741245B (en)
AR (1) AR079050A1 (en)
AU (1) AU2010322478B2 (en)
BR (1) BR112012011518B8 (en)
CA (1) CA2777746C (en)
ES (1) ES2442797T3 (en)
IN (1) IN2012DN03391A (en)
MX (1) MX2012005329A (en)
RU (1) RU2542582C2 (en)
TW (1) TW201121957A (en)
UY (1) UY33037A (en)
WO (1) WO2011062550A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158117A1 (en) * 2011-05-17 2012-11-22 Astrazeneca Ab Combination therapies for treating pain
DK3381917T3 (en) * 2013-01-31 2021-10-18 Bellus Health Cough Inc IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF
WO2015093586A1 (en) * 2013-12-20 2015-06-25 塩野義製薬株式会社 Methods respectively for producing optically active compound having agonistic activity on thrombopoietin receptors and intermediate of said compound
WO2016004358A1 (en) * 2014-07-03 2016-01-07 Afferent Pharmaceuticals, Inc. Methods and compositions for treating diseases and conditions
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
CN108904507A (en) * 2018-02-11 2018-11-30 赖英杰 P2X3 receptor modulators benzimidazole compound is preparing the application in anti-respiratory disorder drug
AU2019416589B2 (en) * 2018-12-29 2023-04-06 Wuhan Ll Science And Technology Development Co., Ltd. Heterocyclic compound intermediate, preparation method therefor and application thereof
CA3131312A1 (en) 2019-02-25 2020-09-03 Bellus Health Cough Inc. Treatment with p2x3 modulators
IL295393A (en) * 2020-02-14 2022-10-01 Bellus Health Cough Inc p2x3 modulators
KR20230051209A (en) * 2020-08-13 2023-04-17 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 Benzimidazole derivatives, their preparation methods and their medical uses
TW202227458A (en) * 2020-12-04 2022-07-16 大陸商上海拓界生物醫藥科技有限公司 Compounds containing fused tricyclic rings and medical use thereof
CN114478508A (en) * 2021-12-31 2022-05-13 淮北师范大学 Crystalline form of a benzimidazole compound
WO2023151660A1 (en) * 2022-02-11 2023-08-17 江苏恒瑞医药股份有限公司 Crystalline form of p2x3 receptor antagonist, and preparation method therefor
WO2023151658A1 (en) * 2022-02-11 2023-08-17 江苏恒瑞医药股份有限公司 Pharmaceutically acceptable salt of p2x3 receptor antagonist and preparation method therefor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6026A (en) * 1849-01-09 Cast-iron car-wheel
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (en) 1996-02-13 1999-07-27 Zeneca Ltd Quinazoline derivative process for the preparation of the same pharmaceutical composition and process for the production of an antiangiogenic effect and / or reduction of vascular permeability in a warm-blooded animal
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
TR200500745T2 (en) 1999-02-10 2005-05-23 Astrazeneca Ab Quinazoline derivatives as inhibitors of vascular development.
SI1249450T1 (en) * 2000-01-17 2008-04-30 Teijin Pharma Ltd Benzimidazole derivatives as human chymase inhibitors
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (en) 2000-06-06 2005-10-17 Астразенека Аб Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition
KR20030022264A (en) 2000-07-07 2003-03-15 앤지오젠 파마슈티칼스 리미티드 Colchinol derivatives as angiogenesis inhibitors
WO2002004434A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
RU2374234C2 (en) * 2004-09-24 2009-11-27 Астразенека Аб Benzimidazole derivatives, compositions containing said derivatives, production and use thereof
MX2009009416A (en) * 2007-03-02 2009-09-11 Schering Corp Benzimidazole derivatives and methods of use thereof.
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
JP2011502148A (en) * 2007-10-31 2011-01-20 メルク・シャープ・エンド・ドーム・コーポレイション P2X3 receptor antagonist for the treatment of pain

Also Published As

Publication number Publication date
ES2442797T3 (en) 2014-02-13
JP5657018B2 (en) 2015-01-21
US8530467B2 (en) 2013-09-10
AU2010322478B2 (en) 2013-11-14
AU2010322478A1 (en) 2012-05-31
CA2777746A1 (en) 2011-05-26
BR112012011518B1 (en) 2020-03-10
US20120289504A1 (en) 2012-11-15
WO2011062550A1 (en) 2011-05-26
EP2501697A1 (en) 2012-09-26
UY33037A (en) 2011-06-30
RU2012124268A (en) 2013-12-27
BR112012011518A2 (en) 2016-06-28
TW201121957A (en) 2011-07-01
AR079050A1 (en) 2011-12-21
RU2542582C2 (en) 2015-02-20
BR112012011518B8 (en) 2023-01-10
CN102741245A (en) 2012-10-17
EP2501697A4 (en) 2013-04-24
JP2013511517A (en) 2013-04-04
CN102741245B (en) 2014-11-05
EP2501697B1 (en) 2013-10-23
CA2777746C (en) 2019-05-14
KR20120113709A (en) 2012-10-15
MX2012005329A (en) 2012-05-29

Similar Documents

Publication Publication Date Title
IN2012DN03391A (en)
TN2012000347A1 (en) 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
GEP20166432B (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
UA106199C2 (en) Aminobenzamide derivatives as agents suitable for controlling animal parasites
UA95644C2 (en) Pyridizinone derivative, pharmaceutical composition and treatment method
JO2962B1 (en) Substituted aminopropionic derivatives as neprilysin inhibitors
UA102179C2 (en) FUNGICIDAL COMPOSITION $ FUNGICIDAL COMPOSITION
UA101819C2 (en) Herbicidal 1h-2-thia-1,5,8-triazanaphthalene-2,2-dioxides
MX2012007935A (en) Fungicidal heterocyclic compounds.
CL2011002840A1 (en) Compound derived from pyrazole carboxamide; fungicidal composition comprising said compound; process for preparing said compound; intermediate compounds; and use of said compound to control phytopathogenic fungi and reduce mycotoxins.
NZ592382A (en) Thioamide compounds, method of making and method of using thereof
BR112012009214A2 (en) compounds
NZ593874A (en) Nalmefene hydrochloride dihydrate
IN2012DN01298A (en)
MY151229A (en) Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
WO2011159124A3 (en) Novel benzoxazole derivative having inhibitory activity against interleukin-6, preparation method thereof, and pharmaceutical composition containing same
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
WO2010056644A8 (en) 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
BR112012012755A2 (en) "Compound of formula (i), fungicidal composition and method for control of crop phytopathogenic fungus"
UA107831C2 (en) Composition for combating plant diseases and its application
UA105022C2 (en) Composition for controlling plant diseases and a method for controlling plant diseases
WO2009145591A3 (en) Phenyl piperazine compounds, pharmaceutical composition including the same, and use thereof
MY173914A (en) Pesticidal composition and method for controlling pests
MY150817A (en) Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid